ライフサイエンスコーパス: rubella

1 memory B cells (MBCs) to mumps, measles, and rubella.

2 tion programs and the control of measles and rubella.

3 tries with the highest burden of measles and rubella.

4 er infectious person for measles, mumps, and rubella.

5 a, and between A. thaliana, A. lyrata and C. rubella.

6 eaks in the USA for measles, chickenpox, and rubella.

7 nd produce dynamic importation risk maps for rubella.

8 rotein), tetanus toxoid, measles, mumps, and rubella.

9 levels of population immunity to measles and rubella.

10 tem is adequate to detect endemic measles or rubella.

11 s, 24% for mumps, and remained unchanged for rubella.

12 ve in 83.7% of HCWs fully vaccinated against rubella.

13 ain in the heart-shaped fruits from Capsella rubella.

14 rus (HSV), varicella zoster virus (VZV), and rubella.

15 measles-rubella group were seropositive for rubella.

16 irus, HSV, and VZV, whereas it was lower for rubella.

17 f IgG was significantly lower for mumps than rubella.

18 (28.4-37.2) for VZV, and 0.15 (0.0-0.8) for rubella.

19 CI, 95%-100%] vs 81% [95% CI, 72%-93%]; and rubella, 100% vs 94% [95% CI, 86%-100%], respectively),

20 s), smallpox (17.7 days), mumps (18.0 days), rubella (18.3 days), and pertussis (22.8 days).

21 ied 2 imported cases of measles, 27 cases of rubella, 309 cases of dengue, and 260 cases of human her

22 ates achieved non-inferiority in both cases (rubella, -4.5% [95% CI -9.5 to -0.1]; yellow fever, 1.2%

23 infants with IgG antibody seroconversion for rubella 6 weeks after vaccination.

24 .03), mumps (168 vs 104 RU/mL; P = .03), and rubella (69 vs 45 IU/mL; P = .01).

25 opulation immunities for measles, mumps, and rubella (92%, 87%, 92%) were similar to the population-i

26 ed species, A. thaliana, A. lyrata, Capsella rubella and Brassica rapa.

27 Capsella rubella and Capsella orientalis emerged independently bu

28 hepatitis A, rheumatic fever, common colds, rubella and chronic sinus infection, in over 200,000 ind

29 accines provides an opportunity to eliminate rubella and congenital rubella syndrome.

30 ate comparative studies and animal models of rubella and congenital rubella syndrome.

31 f data for measles from 2001 to 2011 and for rubella and CRS from 2004 to 2011 covering the US reside

32 on of endemic measles in 2000 and of endemic rubella and CRS in 2004.

33 verifying rubella elimination, high-quality rubella and CRS surveillance needs to be implemented and

34 Rubella and diphtheria seroprotection in MSs were signif

35 egative controls) of the measles, mumps, and rubella and measles, mumps, rubella, and varicella vacci

36 There was partial correlation for rubella and no correlation for mumps.

37 As part the 2012 Nepal measles-rubella and polio SIA, we developed an intervention pack

38 T cell epitopes in the capsid protein of the rubella and ruhugu viruses are moderately to highly cons

39 h is an outgroup to the clade that comprises rubella and ruhugu viruses, was found in acutely encepha

40 separately administered measles, mumps, and rubella and varicella vaccines.

41 The rubella and yellow fever antibody titres were reduced by

42 ogenicity of IPV given alongside the measles-rubella and yellow fever vaccines at 9 months and when g

43 rected against congenital disease (including rubella and Zika) may be instructive.

44 BCs was 5 to 10 times lower than measles and rubella, and 10% of the participants had no detectable M

45 easles, 2.7 months for mumps, 3.9 months for rubella, and 3.4 months for varicella.

46 ion of seven TPSs from A. thaliana, Capsella rubella, and Brassica oleracea in Nicotiana benthamiana

47 o verify the elimination of endemic measles, rubella, and congenital rubella syndrome (CRS) from the

48 Annual numbers of measles, rubella, and CRS cases, by importation status, outbreak

49 ded that the elimination of endemic measles, rubella, and CRS from the United States was sustained th

50 mine whether elimination of endemic measles, rubella, and CRS had been sustained.

51 for diphtheria, tetanus, pertussis, measles, rubella, and Haemophilus influenzae type b vaccine antig

52 already connected with those of measles and rubella, and transitioning existing capabilities to meas

53 The BioPlex 2200 measles, mumps, rubella, and varicella (MMRV) IgG assay (Bio-Rad Laborat

54 completion by age 2 years of measles, mumps, rubella, and varicella immunization may offer improved d

55 The combination measles, mumps, rubella, and varicella vaccine is associated with a 2-fo

56 he analysis of vaccine type, measles, mumps, rubella, and varicella vaccine was associated with a 1.4

57 sles, mumps, and rubella and measles, mumps, rubella, and varicella vaccines among children who are 1

58 litative diagnostic test for measles, mumps, rubella, and varicella virus immunity, in this study, we

59 measures antibodies against measles, mumps, rubella, and varicella viruses simultaneously.

60 Mumps, measles, rubella, and varicella-zoster viruses (MMRV) may cause s

61 Immunity to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV) is a c

62 (1.9%) were seronegative for measles, mumps, rubella, and VZV, respectively, and 165 (14%) were seron

63 HCWs presumptively immune to measles, mumps, rubella, and VZV, the Bio-Rad MFI was positive in 77.3,

64 % for poliovirus seroprevalence and measles, rubella, and yellow fever seroconversion, and (1/3) log2

65 neumoniae, rotavirus, measles, meningitis A, rubella, and yellow fever to approximate the future deat

66 the future co-administration of IPV, measles-rubella, and yellow fever vaccines within the Expanded P

67 andomly assigned to receive the IPV, measles-rubella, and yellow fever vaccines, singularly or in com

68 post-vaccination serum samples for measles, rubella, and yellow fever; and the post-vaccination anti

69 f US population seropositive for measles and rubella; and measles-mumps-rubella vaccination coverage

70 Vaccine-induced measles and rubella antibody responses are not negatively affected b

71 ondary objectives included noninferiority of rubella antibody seroconversion and evaluating rotavirus

72 Like in Arabidopsis, PEGs in C. rubella are frequently associated with the presence of t

73 Measles and rubella are important causes of morbidity and mortality

74 Anti-rubella assays have variable formats, including antigens

75 ated species Arabidopsis lyrata and Capsella rubella Based on the quantitative analysis metrics, we i

76 such reductions as vaccination programs for rubella become widespread in mainland China.

77 dy avidity indexes were high for measles and rubella but low for mumps.

78 vaccinated against MMR (measles, mumps, and rubella), but were confirmed in measles-infected macaque

79 of floral scent has been lost in selfing C. rubella by mutation of cinnamate-CoA ligase CNL1.

80 age of rubella infection; thereby increasing rubella cases among pregnant women and the resulting con

81 ty-eight percent of measles cases and 54% of rubella cases were internationally imported or epidemiol

82 sles-negative samples that were confirmed as rubella cases.

83 the Brassicaceae species Capsella (Capsella rubella), caused postmeiotic arrest of pollen developmen

84 twice independently by point mutations in C. rubella, causing a loss of enzymatic activity.

85 i-valent seroprevalence data for measles and rubella, collected 2 years and 3 months after a mass mea

86 nd 97% (95% CR: 90-100%) for the measles and rubella components respectively, with an estimated cover

87 those other congenital infections, including rubella, congenital cytomegalovirus, human immunodeficie

88 ated innate and adaptive immune responses to rubella-containing vaccine and their association with ha

89 tionally, we provide novel information about rubella-containing vaccine immunogenetics and review the

90 Rubella-containing vaccine is highly effective and safe

91 idence of CRS is higher in countries with no rubella-containing vaccines (RCV) in their immunization

92 major cause of child mortality globally, and rubella continues to be the leading infectious cause of

93 Therefore, it gives us the idea that the rubella control and elimination goal should be achieved

94 eminar, we provide present results regarding rubella control, elimination, and eradication policies,

95 MO protease, HEARTBREAK (HTB), from Capsella rubella controls the activity of the key regulator of fr

96 amnionitis, toxoplasmosis, other infections, rubella, cytomegalovirus infection, and herpes simplex v

97 um, parvovirus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and Herpesviruses are a major

98 fferential diagnosis included toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus, syphilis

99 Serologic testing ruled out toxoplasmosis, rubella, cytomegalovirus, syphilis, and human immunodefi

100 Toxoplasmosis, rubella, cytomegalovirus, syphilis, and human immunodefi

101 Seroprevalence rates of mumps, measles, and rubella determined by IgG enzyme-linked immunosorbent as

102 mong 1- to 6-year-olds was high for measles, rubella, diphtheria, and tetanus (91%-98%; 95% confidenc

103 to estimate seroprotection against measles, rubella, diphtheria, and tetanus, using Luminex multiple

104 measles and rubella, or measles, mumps, and rubella) during pregnancy, confirming the findings of an

105 nal Verification Commissions for Measles and Rubella elimination advocate that the time for courageou

106 s an important benefit of global measles and rubella elimination and polio eradication strategies.

107 se results will be important for measles and rubella elimination and the expansion of Japanese enceph

108 tioning existing capabilities to measles and rubella elimination efforts allows for optimized use of

109 s that should be transitioned to measles and rubella elimination efforts.

110 plicated to independently verify measles and rubella elimination in the regions and globally.

111 es between polio elimination and measles and rubella elimination include the use of an extensive surv

112 Measles and rubella elimination strategies rely heavily on achieving

113 ogram has diversified to address measles and rubella elimination, data management and quality, and st

114 As the foundation to achieving and verifying rubella elimination, high-quality rubella and CRS survei

115 To achieve rubella elimination, supplemental immunization activitie

116 Measles and rubella eradication is feasible and cost saving.

117 ver virus, the present results indicate that rubella exhibits a large degree of pleomorphy.

118 WHO convened a meeting of experts in the rubella field to discuss the use of RUBI-1-94 and the po

119 Measles genotype B3 and rubella genotype 2B were detected.

120 507) was non-inferior to that in the measles-rubella group (473 [94%] of 506 infants; difference 0.8%

121 507) was non-inferior to that in the measles-rubella group (499 [99%] of 506; difference -0.8% [90% C

122 bella plus LJEV group and 506 in the measles-rubella group completed the study.

123 EV group and one (<1%) of 506 in the measles-rubella group were seropositive for measles; eight (2%)

124 plus LJEV group and two (<1%) in the measles-rubella group were seropositive for rubella.

125 oup; 108 [21%] of 506 infants in the measles-rubella group).

126 p) or measles-rubella vaccine alone (measles-rubella group).

127 bella plus LJEV group and 548 to the measles-rubella group.

128 The genome sequence of C. rubella has recently been released, which allows charact

129 rs vaccinated against measles and, possibly, rubella have lower concentrations of maternal antibodies

130 ptively immune to measles, mumps, and VZV (a rubella IFA was unavailable).

131 of the first international standard for anti-rubella IgG (RUBI-1-94), new rubella vaccines have been

132 thods used to measure concentrations of anti-rubella IgG have also evolved to rapid, high-throughput

133 positive by the Bio-Rad measles, mumps, and rubella IgG MFIs, respectively.

134 lth care providers should suspect measles or rubella in patients with febrile rash illness, especiall

135 The median R0 of rubella in the African region is 5.2, with 90% of countr

136 Poland had the highest incidence of rubella in the WHO European Region in 2007 and 2008.

137 Since 2004, rubella incidence has been below 1 case per 10,000,000 p

138 We reviewed rubella incidence in Poland since 1966 and analyzed nati

139 Using a rich data source of rubella incidence, we show that patterns of population t

140 utside of Greece, the centre of origin of C. rubella, indicating that they arose before its geographi

141 Measles and rubella induced high-avidity antibodies and mumps induce

142 n countries based on the age distribution of rubella infection using Bayesian hierarchical models.

143 ludes disorders associated with intrauterine rubella infection.

144 equate coverage can raise the average age of rubella infection; thereby increasing rubella cases amon

145 The decrease in discharges for rubella is most likely due to the MMR vaccine.

146 ncerns about future zoonotic transmission of rubella-like viruses, but will facilitate comparative st

147 nfidence miRNA candidates specific to the C. rubella lineage.

148 Persistence of rubella live vaccine has been associated with chronic sk

149 l effects, including naproxen, ibuprofen and rubella live vaccine.

150 , and rubella (MMR-II), measles (Attenuvax), rubella (Meruvax-II), rotavirus (Rotateq and Rotarix), a

151 FSs in toddlers given MMRV and measles-mumps-rubella (MMR) and a national cohort study of vaccine cov

152 Vaccination against measles, mumps, and rubella (MMR) and yellow fever (YF) with live attenuated

153 not be protected against measles, mumps, and rubella (MMR) because of impaired initial vaccine respon

154 a 2-dose pediatric schedule of measles-mumps-rubella (MMR) or measles-mumps-rubella-varicella (MMRV)

155 Increasing measles-mumps-rubella (MMR) vaccination among departing US travelers c

156 sing the case example of measles, mumps, and rubella (MMR) vaccination and measles.

157 Measles-mumps-rubella (MMR) vaccination coverage with at least a singl

158 the effects of live attenuated measles-mumps-rubella (MMR) vaccination on disease activity in patient

159 To protect young infants, measles-mumps-rubella (MMR) vaccination was offered to those aged 6-14

160 revention on coverage of measles, mumps, and rubella (MMR) vaccination, nonmedical exemption, and med

161 ntroduction of PCR testing and measles-mumps-rubella (MMR) vaccination.

162 s adverse event following measles, mumps and rubella (MMR) vaccination.

163 ve-virus vaccines such as measles, mumps and rubella (MMR) vaccination.

164 Measles-mumps-rubella (MMR) vaccinations have been offered to Finnish

165 Measles-mumps-rubella (MMR) vaccine (given as either MMR or measles-mu

166 ypothesized link between the measles, mumps, rubella (MMR) vaccine and autism continues to cause conc

167 ch showing no link between the measles-mumps-rubella (MMR) vaccine and autism spectrum disorders (ASD

168 Two doses of measles, mumps, and rubella (MMR) vaccine are 97% effective against measles,

169 journal, suggested that measles, mumps, and rubella (MMR) vaccine causes autism.

170 Routinely, the first measles, mumps, and rubella (MMR) vaccine dose is given at 14 months of age

171 The combined measles, mumps, and rubella (MMR) vaccine has been successfully administered

172 following introduction of the measles-mumps-rubella (MMR) vaccine in 1988.

173 e introduction of the two-dose measles-mumps-rubella (MMR) vaccine in 1996, and the implementation of

174 ist on the safety of the measles, mumps, and rubella (MMR) vaccine in adults.

175 effect of a third dose of the measles-mumps-rubella (MMR) vaccine in stemming a mumps outbreak is un

176 The measles-mumps-rubella (MMR) vaccine is effective in eliciting a good a

177 6 weeks after receipt of measles, mumps, and rubella (MMR) vaccine were tested for the ability to neu

178 e schedule with or without the measles-mumps-rubella (MMR) vaccine, the MMR vaccine only, and the exp

179 ered eligible to receive the measles, mumps, rubella (MMR) vaccine.

180 erosal, and/or receiving the measles, mumps, rubella (MMR) vaccine.

181 had the recommended 2 doses of mumps-measles-rubella (MMR) vaccine.

182 one or two doses of the measles, mumps, and rubella (MMR) vaccine; and proportions with medical or p

183 2), varicella (Varivax), measles, mumps, and rubella (MMR-II), measles (Attenuvax), rubella (Meruvax-

184 thousand immunized (2 doses of measles-mumps-rubella [MMR] vaccine) students and residents were teste

185 For rubella, mothers in the orthodox communities had higher

186 , Hepatitis B vaccine (HBV), Polio, Measles, Rubella, Mumps, trivalent MMR vaccine and Haemophilus in

187 tive agent of the childhood disease known as rubella or German measles.

188 theria, and acellular pertussis, measles and rubella, or measles, mumps, and rubella) during pregnanc

189 ]) and rubella seroconversion in the measles-rubella plus LJEV group (478 [94%] of 507) was non-infer

190 ation, measles seroconversion in the measles-rubella plus LJEV group (496 [98%] of 507) was non-infer

191 s assigned to each group, 507 in the measles-rubella plus LJEV group and 506 in the measles-rubella g

192 s, 545 were randomly assigned to the measles-rubella plus LJEV group and 548 to the measles-rubella g

193 tion, six (1%) of 507 infants in the measles-rubella plus LJEV group and one (<1%) of 506 in the meas

194 r measles; eight (2%) infants in the measles-rubella plus LJEV group and two (<1%) in the measles-rub

195 lla vaccine and LJEV simultaneously (measles-rubella plus LJEV group) or measles-rubella vaccine alon

196 vent (97 [19%] of 507 infants in the measles-rubella plus LJEV group; 108 [21%] of 506 infants in the

197 Rubella remains a significant burden in mainland China.

198 Rubella remains an important pathogen worldwide, with ro

199 l epitopes in the fusion (E1) protein of the rubella, ruhugu and rustrela viruses and two putative T

200 ; difference -0.8% [90% CI -2.6 to 1.1]) and rubella seroconversion in the measles-rubella plus LJEV

201 l {CI}, 52%-62%] vs 99% [95% CI, 96%-100%]), rubella seroprotection (65% [95% CI, 60%-70%] vs 98% [95

202 by plaque reduction neutralization assay and rubella seroprotection and mumps seropositivity by enzym

203 Predictors of rubella seroprotection and mumps seropositivity were sim

204 amelineae in the Brassicaceae, with Capsella rubella serving as an outgroup to the genus Arabidopsis.

205 the Brassicaceae: the heart-shaped Capsella rubella silicle and the near-cylindrical Arabidopsis tha

206 as part of the 2012-2020 global measles and rubella strategic plan.

207 45 responding Member States have nationwide rubella surveillance, and 39 (87%) have nationwide CRS s

208 Congenital rubella syndrome (CRS) case identification is challengin

209 of endemic measles, rubella, and congenital rubella syndrome (CRS) from the Western hemisphere, the

210 pregnant women and the resulting congenital rubella syndrome (CRS) in their newborns.

211 Congenital rubella syndrome (CRS) includes disorders associated wit

212 a virus in a 28-year-old man with congenital rubella syndrome (CRS), who presented with blurred visio

213 de, with roughly 100,000 cases of congenital rubella syndrome estimated to occur every year.

214 ortunity to eliminate rubella and congenital rubella syndrome.

215 and animal models of rubella and congenital rubella syndrome.

216 orse for chickenpox, and 5.8 times worse for rubella than would be expected in a pre-vaccine era in w

217 ing from adding surveillance for measles and rubella to integrated disease surveillance for outbreak-

218 effective and safe and, as a result, endemic rubella transmission has been interrupted in the America

219 We developed an age specific model of rubella transmission to predict the level of R0 that wou

220 mL, CD4% >/=15, and >/=1 prior measles-mumps-rubella vaccination (MMR) were given another MMR.

221 ith humoral immune response variations after rubella vaccination (P = 8.62 x 10(-8)).

222 fferences in neutralizing antibody levels to rubella vaccination and represent a validation of our pr

223 ed 2 years and 3 months after a mass measles-rubella vaccination campaign in Lao PDR to estimate the

224 If routine measles-rubella vaccination coverage is suboptimal or if gaps in

225 e for measles and rubella; and measles-mumps-rubella vaccination coverage levels.

226 s have been developed and global coverage of rubella vaccination has increased.

227 Incomplete rubella vaccination programmes result in continued disea

228 Despite a safe and effective vaccine, rubella vaccination programs with inadequate coverage ca

229 MCs from high and low antibody responders to rubella vaccination to delineate transcriptional differe

230 Typhoid or measles-mumps-rubella vaccination was associated with lower anti-nonGa

231 erage for measles vaccine before introducing rubella vaccination, and highlight the importance of mai

232 se series in Lancet connecting measles-mumps-rubella vaccinations with autism, small case series do n

233 ccine (V) dose given after one measles-mumps-rubella vaccine (MMR) dose (MMR + V), versus two MMR dos

234 A third measles-mumps-rubella vaccine (MMR) dose (MMR3) is recommended in the

235 accination with the live measles, mumps, and rubella vaccine (MMR) is associated with a lower rate of

236 Measles, mumps, and rubella vaccine (MMR) or immune globulin (IG) are routin

237 and safety of a third dose of measles-mumps-rubella vaccine (MMR-3) in 150 young adults.

238 ity of concomitant administration of measles-rubella vaccine (MR) and a third dose of human rotavirus

239 ults, we summarize the safety of introducing rubella vaccine across demographic and coverage contexts

240 f seizures compared with measles, mumps, and rubella vaccine administered with or without varicella v

241 (measles-rubella plus LJEV group) or measles-rubella vaccine alone (measles-rubella group).

242 ed States, including (1) measles, mumps, and rubella vaccine and autism; (2) thimerosal, a mercury-ba

243 cted and geocoded tweets about measles-mumps-rubella vaccine and classified their sentiment using mac

244 In China, measles-rubella vaccine and live attenuated SA 14-14-2 Japanese

245 mly assigned (1:1) to receive either measles-rubella vaccine and LJEV simultaneously (measles-rubella

246 (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months.

247 vaccinated populations (2-dose measles-mumps-rubella vaccine coverage >=85%).

248 provide guidance on the safe introduction of rubella vaccine into countries in the face of substantia

249 exposed to the live-attenuated measles-mumps-rubella vaccine regardless of route of administration.

250 fied, additional mass campaigns with measles-rubella vaccine will be necessary.

251 ammatory genes that may assist in explaining rubella vaccine-induced immune response variations.

252 nths of age on the immunogenicity of measles-rubella vaccine.

253 nts who were vaccinated (measles, mumps, and rubella vaccine/tick-borne encephalitis vaccine/BCG vacc

254 Immune responses to current rubella vaccines demonstrate significant inter-individua

255 andard for anti-rubella IgG (RUBI-1-94), new rubella vaccines have been developed and global coverage

256 Use of combined measles-rubella vaccines provides an opportunity to eliminate ru

257 safety with co-administered LJEV and measles-rubella vaccines supports the co-administration of these

258 nical trial (NCT01681992) of 2 measles-mumps-rubella vaccines were used to compare anti-mumps antibod

259 measles-mumps-rubella (MMR) or measles-mumps-rubella-varicella (MMRV) vaccine was assessed in childre

260 bination vaccines, such as the measles-mumps-rubella-varicella (MMRV) vaccine, into immunization sche

261 acy of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV), one live attenuated va

262 aricella vaccine or a combined measles-mumps-rubella-varicella vaccine (MMRV).

263 accine (given as either MMR or measles-mumps-rubella-varicella vaccine and collectively referred to a

264 fruit development, INDEHISCENT (CrIND in C. rubella), via de-SUMOylation.

265 o examine the three-dimensional structure of rubella virions and compare their structure to that of R

266 While many rubella virions are approximately spherical and have dim

267 nalyses to show that approximately spherical rubella virions lack the icosahedral organization which

268 gins of the disease and its causative agent, rubella virus (Matonaviridae: Rubivirus), have remained

269 ldren since laboratory markers of congenital rubella virus (RUBV) infection do not persist beyond age

270 Rubella virus (RUBV), a positive-strand RNA virus, repli

271 Rubella virus (RV) is a leading cause of birth defects d

272 Immunity to rubella virus (RV) is commonly determined by measuring s

273 opositive for measles virus, mumps virus, or rubella virus antibodies, and there were no significant

274 The ectodomains of the rubella virus glycoproteins, E1 and E2, are shown to be

275 100.0% and 99.6%, respectively, showed anti-rubella virus immunoglobulin G (IgG) seroprotection.

276 is the first to show persistent intraocular rubella virus in a 28-year-old man with congenital rubel

277 There is growing evidence for the role of rubella virus in Fuchs' uveitis syndrome (FUS).

278 Vaccination with live attenuated rubella virus induces a strong immune response in most i

279 Rubella virus is the only member of the Rubivirus genus

280 We also show that the rubella virus nucleocapsid structure often forms a rough

281 ntial barriers between host species and that rubella virus probably has a zoonotic origin.

282 bly pathway, leads to an organization of the rubella virus structural proteins that is different from

283 share an identical genomic architecture with rubella virus(2,3).

284 for 12 viruses: measles virus, mumps virus, rubella virus, respiratory syncytial virus, alphavirus a

285 ment: cytomegalovirus, herpes simplex virus, rubella virus, Toxoplasma gondii, and Zika virus.

286 hugu virus, which is the closest relative of rubella virus, was found in apparently healthy cyclops l

287 ults indicate that the assembly mechanism of rubella virus, which has previously been shown to differ

288 leotide polymorphisms (SNPs) associated with rubella virus-specific neutralizing antibodies.

289 ndividual differences in humoral immunity to rubella virus.

290 our knowledge, the first known relatives of rubella virus.

291 e post-fusion state predicts that ruhugu and rubella viruses have a similar capacity for fusion with

292 Rubella viruses of genotypes 1E and 2B are currently the

293 he whole genomic characterization of Chinese rubella viruses was clarified.

294 The results indicated that the Chinese rubella viruses were highly conserved at the genomic lev

295 Since 1814, when rubella was first described, the origins of the disease

296 The WHO international standard for anti-rubella was first established in the 1960s when clinical

297 rculating antibodies for measles, mumps, and rubella was measured with enzyme immunoassays, and the a

298 % of paternally expressed genes (PEGs) in C. rubella were commonly imprinted in both species, reveali

299 he genome-wide imprinting status of Capsella rubella, which shared a common recent ancestor with Arab

300 iseases (VPDs), including polio, measles and rubella, yellow fever, Japanese encephalitis, rotavirus,